报告人： Professor Yong-Hee Kim
Global trends in biotherapeutics are currently focused on next-generation therapeutics such as genetic therapeutics, mRNA vaccines, and immunotherapy. Larger pharmaceutical companies have shown increased interest in the development and delivery systems of novel biotherapeutics.
One area of focus is gene therapy, which has rapidly emerged due to advancements in genetic engineering and nanotechnology. However, there are still challenges related to storage, maintenance, and effectiveness caused by the unstable structure of genetic materials and limitations of gene carriers. Previously, we have reported the effectiveness of a gene carrier based on nona-arginine (9R) with disease cell-targeted gene delivery combined with genetic materials. Oligopeptides targeting specific receptors were conjugated with 9R, facilitating successful internalization of genetic materials in various disease models. This research suggests that new delivery platforms based on oligo-arginine peptide/gene complexes with targeting peptides can enable effective delivery of therapeutic genes to specific disease cells in vivo, with promising outcomes anticipated in future translational studies.
In addition to gene therapy, research has been conducted on targetable nano- and micro-particular systems for the delivery of hydrophobic or hydrophilic drugs. Recent studies have explored PLGA nanoparticles decorated with single-chain variable fragments (scFv) or cell surface protein targeting oligopeptides for accurate drug delivery to target cells. For example, CD64 scFv-mediated HO-1 inhibitor delivery demonstrated chemo-sensitization in leukemia cells and immune activation of myeloid cells, suggesting potential for combination therapy. Similarly, nanoparticles conjugated with prohibitin binding peptide (PBP) efficiently targeted prohibitin overexpressed fatty liver and obese adipose tissue in a nonalcoholic steatohepatitis (NASH) model, leading to improvements in obesity, insulin resistance, and steatohepatitis.
Advancements in micro-resolution 3D printers have also played a significant role in the development of complex and mass-producible drug delivery platforms. Traditional methods of fabricating dissolvable microneedles (MNs) using micro-milling machineries have limitations in terms of drug delivery accuracy. We have reported a novel projection micro-stereolithography 3D printer-based self-locking MN to overcome these limitations. This technology allows for precise skin insertion, adhesion, and transcutaneous microdose drug delivery.
Overall, these advancements in biotherapeutics and drug delivery systems, such as gene carriers, nanoparticles, and 3D printing technologies, hold promise for the development of more effective and targeted therapies for various diseases.
After receiving Ph.D. under the supervision of Professor William I. Higuchi, Prof. Yong-Hee Kim joined the late Professor Sung Wan Kim’s lab as a Postdoctoral Fellow in the Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, USA. Currently, he is a Professor and HYU Distinguished Research Fellow at the Department of Bioengineering, and Director of the Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, Korea. He is a Distinguished Scientist (Einstein Professorship) for Chinese Academy of Sciences (CAS) President's International Fellowship Initiative, China. His research interests are focused on developing Novel Biopharmaceutical Delivery Platforms including Non-viral Gene Delivery (plasmid DNA, siRNA, mRNA), Targetable Nano- and Micro-particular Systems, Immunomodulatory Combination Therapy, Transdermal Micro-array Systems, Targeted Oral Gene Delivery, Fusion Protein Delivery, and Injectable In-situ Gel Depot System. His scientific activities are Co-chair of the 2024 World Biomaterials Congress Organizing Committee, Fellow of the International Union of Societies for Biomaterials Science and Engineering, Former President of the Korean Society for Biomaterials, and Editorial Board Members of the Biomaterials and Archives of Pharmacal Research.